Chang Gung University

Chang Gung University of Science and Technology

Kaohsiung Medical University

Other

Tsong-Long Hwang

Fang-Rong Chang

Pei-Wen Hsieh

Yu-Chia Chang

Yang-Chang Wu

Cherng-Chyi Tzeng

Chun-Yu Chen

Yeh-Long Chen

Chin-Chung Wu

Ting-Yi Wang

Shih-Wei Wang

Yi-Hong Tsai

Chih-Hua Tseng

Chih-Hsin Wang

Bing-Hung Chen

Yuan-Bin Cheng

Yin-Ting Huang

Chih-Hao Hung

Wen-Hui Wang

Kartiko Arif Purnomo

Yu-Li Chen

Kuei-Hung Lai

Ya-Xuan Wang

Yung-Fong Tsai

Po-Jen Chen

Liang-Mou Kuo

A method for inhibiting inflammatory in a subject is provided, comprising: administering a pharmaceutical composition comprising an effective amount of 9,11-secosteroids.

9,11-secosteroids and the use of 9,11-secosteroids in preparing pharmaceutical compositions for inhibiting inflammation

Disclosed herein is a method of treating diseases and/or disorders associated with the activation of inflammasomes. The method includes administering to a subject in need thereof an effective amount of 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)-carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, a salt, a solvate or an ester thereof.

Methods for the treatment of diseases associated with activation of inflammasomes

A method for inhibiting infection of SARS-CoV-2 in a subject is provided, comprising administering an effective amount of plant extract, wherein the plant extract comprises an alcohol extract of the herbal of Menispermaceae, wherein the herbal of Menispermaceae isor

Method for inhibiting infection of SARS-CoV-2 in a subject

The present invention relates to a maca extract and uses thereof. The part of the maca extract extracted with polar solvent has anti-thrombotic activity, the part of the maca extract extracted with medium and low polarity solvents has anti-neutrophilic inflammatory and anti-allergic activities, the part of the maca extract extracted with low polarity solvent has anti-neutrophilic inflammatory activity and has pro-angiogenic activity.

Maca extract and use thereof

The invention provides a pharmaceutical composition for treating phosphodiesterase 4-mediated (PDE4-mediated) disease in a patient and inhibition of phosphodiesterase 4 (PDE4) activity. The pharmaceutical composition includes an effective amount of Ribociclib and a pharmaceutically acceptable carrier. The invention further provides a use of the pharmaceutical composition for treating PDE4-mediated disease in a patient. The application of the pharmaceutical composition of the present invention and use thereof are advantageous for inhibiting of PDE4 activity and thus treating a PDE4-mediated disease.

Pharmaceutical composition and use for applying ribociclib in phosphodiesterase 4-mediated disease treatment of patient and inhibition of phosphodiesterase 4 activity

Disclosed herein are compounds of formula (I), and pharmaceutical compositions comprising the same. The compounds of formula (I) are neutrophilic inflammation inhibitors, thus, they are useful for treatment and/or prophylaxis of inflammatory diseases and/or disorders associated with abnormal activation of neutrophils, such as ARDS, ALI, COPD, lung fibrosis, chronic bronchitis, pulmonary emphysema, &#x3b1;-1 anti-trypsin deficiency, cystic fibrosis, idiopathic pulmonary fibrosis, liver injury, steatohepatitis, liver fibrosis, damages caused by ischemia and reperfusion, myocardial infarction, shock, stroke, and organ transplantation, ulcerative cholitis, vasculitis, SLE, sepsis, SIRS, arthritis, psoriasis, atopic dermatitis, and inflammatory skin diseases. 

Neutrophil inflammation inhibitor and uses thereof

Disclosed herein are novel formyl peptide receptor 1 (FPR1) antagonists and their uses in manufacturing medicaments for the treatment and/or prophylaxis of diseases and/or disorders mediated by FPR1.

Formyl peptide receptor 1 antagonists and uses thereof

A dipeptide derivative as formyl peptide receptor 1 (FPR1) antagonist is provided. The dipeptide derivative is represented by formula (I), 

FPR1 antagonist derivatives and use thereof

An oxime-based compound having the following formula (I) or a pharmaceutically acceptable salt thereof: 

Oxime-based compound, pharmaceutical composition containing the same and method for preparing the same

Growing community of inventors

Taoyuan, Taiwan

Tsong-Long Hwang